Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625833 · ClinicalTrials.gov registry record · Phase 2
A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
NCT00625833 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 330 participants.
The verdict
NCT00625833, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
Study Summary
This is a trial to investigate the effectiveness and safety of \[S,S\]-Reboxetine in relieving chronic peripheral pain suffered by patients with diabetes. Some evidence for the effectiveness of \[S,S\]- Reboxetine in relieving chronic pain has been seen in 3 completed trials.
Interventions
- DRUG Placebo
- DRUG [S,S]-Reboxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00625833
The ClinicalTrials.gov registry entry for NCT00625833 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00625833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00625833 about?
NCT00625833 is a clinical study titled "A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.". This is a trial to investigate the effectiveness and safety of \[S,S\]-Reboxetine in relieving chronic peripheral pain suffered by patients with diabetes. Some evidence for the effectiveness of \[S,S\]- Reboxetine in relieving chronic pain has been seen in 3 completed trials.
What is the current status of trial NCT00625833?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2007-12. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00625833?
The interventions under investigation include: Placebo (DRUG), [S,S]-Reboxetine (DRUG).
Who is sponsoring clinical trial NCT00625833?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.